Open label randomized phase III study of weekly docetaxel and docetaxel every 3 weeks in patients with metastatic breast cancer, resistant to prior chemotherapy.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2011
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TAX-613
- 12 Oct 2009 New source identified and integrated (Netherlands Trial Register) (NTR1944).
- 23 Aug 2009 Planned initiation date changed from 1 Feb 2001 to 18 Jul 2000 as reported by Netherlands Trial Register.
- 23 Aug 2009 Planned end date changed from 1 Apr 2006 to 1 Jan 2008 as reported by Netherlands Trial Register.